Sponsored by
This is a UK story, but we see this happen to patients every day in the US. Clinical trial inclusion/exclusion criteria are extremely rigid, and only a small percentage of brain tumor patients are able to qualify for the most promising trials. It's heartbreaking, and it's exactly why we need everyone's support for the Promising Pathway Act.